{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T03:37:04Z","timestamp":1773200224471,"version":"3.50.1"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T00:00:00Z","timestamp":1656374400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016545","name":"F Hoffmann-La Roche Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016545","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.ijid.2022.06.045","type":"journal-article","created":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T02:06:33Z","timestamp":1656727593000},"page":"585-592","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19"],"prefix":"10.1016","volume":"122","author":[{"given":"Flonza","family":"Isa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Forleo-Neto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4190-9803","authenticated-orcid":false,"given":"Jonathan","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjun","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle","family":"Armas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaru","family":"Oshita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia","family":"Brinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Folkerth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lori","family":"Faria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingeborg","family":"Heirman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neena","family":"Sarkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2949-211X","authenticated-orcid":false,"given":"Bret J.","family":"Musser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shikha","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meagan P.","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth C.","family":"Turner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3037-1959","authenticated-orcid":false,"given":"Samit","family":"Ganguly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adnan","family":"Mahmood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajla","family":"Dupljak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea T.","family":"Hooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1236-5245","authenticated-orcid":false,"given":"Jennifer D.","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunji","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bari","family":"Kowal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhwen","family":"Soo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory P.","family":"Geba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leah","family":"Lipsich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ned","family":"Braunstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George D.","family":"Yancopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Weinreich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary A.","family":"Herman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2022.06.045_bib0001","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/j.cell.2020.10.049","article-title":"Case study: prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised individual with","volume":"183","author":"Avanzato","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ijid.2022.06.045_bib0002","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2022.06.045_bib0003","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1126\/science.abd0831","article-title":"Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies","volume":"369","author":"Baum","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ijid.2022.06.045_bib0004","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20210198","article-title":"SARS-CoV-2 spike therapeutic antibodies in the age of variants","volume":"218","author":"Baum","year":"2021","journal-title":"J Exp Med"},{"key":"10.1016\/j.ijid.2022.06.045_bib0005","doi-asserted-by":"crossref","first-page":"e389","DOI":"10.1016\/S2352-3026(21)00110-1","article-title":"Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma","volume":"8","author":"Bird","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.ijid.2022.06.045_bib0006","unstructured":"Centers for Disease Control and Prevention, Underlying medical conditions associated with high risk for severe COVID-19: information for healthcare professionals. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/hcp\/clinical-care\/underlyingconditions.html, 2021a (accessed 3 November 2021)."},{"key":"10.1016\/j.ijid.2022.06.045_bib0007","unstructured":"Centers for Disease Control and Prevention, Interim clinical considerations for use of COVID-19 vaccines currently authorized in the United States. https:\/\/www.cdc.gov\/vaccines\/covid-19\/clinical-considerations\/covid-19-vaccines-us.html, 2021b (accessed 3 November 2021)."},{"key":"10.1016\/j.ijid.2022.06.045_bib0008","unstructured":"Centers for Disease Control and Prevention, Interim infection prevention and control recommendations to prevent SARS-CoV-2 spread in nursing homes. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/hcp\/long-term-care.html, 2021c (accessed 3 November 2021)."},{"key":"10.1016\/j.ijid.2022.06.045_bib0009","doi-asserted-by":"crossref","first-page":"3949","DOI":"10.1016\/j.cell.2021.06.002","article-title":"The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies","volume":"184","author":"Copin","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.ijid.2022.06.045_bib0010","unstructured":"Food and Drug Administration, Coronavirus (COVID-19) update: FDA authorizes monoclonal antibody for treatment of COVID-19. https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibody-treatment-covid-19, 2020 (accessed 25 August 2021)."},{"key":"10.1016\/j.ijid.2022.06.045_bib0011","unstructured":"Food and Drug Administration, FDA authorizes REGEN-COV monoclonal antibody therapy for post-exposure prophylaxis (prevention) for COVID-19. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-authorizes-regen-cov-monoclonal-antibody-therapy-post-exposure-prophylaxis-prevention-covid-19, 2021 (accessed 25 August 2021)."},{"key":"10.1016\/j.ijid.2022.06.045_bib0012","unstructured":"Food and Drug Administration. Emergency Use Authorization 091. https:\/\/www.fda.gov\/media\/145610\/download, 2022 (accessed 10 February 2022)."},{"key":"10.1016\/j.ijid.2022.06.045_bib0013","unstructured":"GOV.UK, Summary of product characteristics for Ronapreve. https:\/\/www.gov.uk\/government\/publications\/regulatory-approval-of-ronapreve\/summary-of-product-characteristics-for-ronapreve, 2021 (accessed 1 December 2021)."},{"key":"10.1016\/j.ijid.2022.06.045_bib0014","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1126\/science.abd0827","article-title":"Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail","volume":"369","author":"Hansen","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ijid.2022.06.045_bib0015","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1001\/jama.2016.16477","article-title":"Prevalence of immunosuppression among US adults, 2013","volume":"316","author":"Harpaz","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.ijid.2022.06.045_bib0016","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ijid.2022.06.045_bib0018","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/jama.2021.7515","article-title":"Bamlanivimab for prevention of COVID-19","volume":"326","author":"Kuritzkes","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.ijid.2022.06.045_bib0019","unstructured":"Lontok K. American Society for Microbiology, How effective are COVID-19 vaccines in immunocompromised people? https:\/\/asm.org\/Articles\/2021\/August\/How-Effective-Are-COVID-19-Vaccines-in-Immunocompr, 2021 (accessed 1 September 2021)."},{"key":"10.1016\/j.ijid.2022.06.045_bib0020","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1213\/ANE.0000000000004845","article-title":"Coronaviruses and SARS-CoV-2: a brief overview","volume":"131","author":"Ludwig","year":"2020","journal-title":"Anesth Analg"},{"key":"10.1016\/j.ijid.2022.06.045_bib0021","doi-asserted-by":"crossref","first-page":"n2098","DOI":"10.1136\/bmj.n2098","article-title":"Covid-19: 40% of patients with weakened immune system mount lower response to vaccines","volume":"374","author":"Munro","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ijid.2022.06.045_bib0023","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1056\/NEJMoa2109682","article-title":"Subcutaneous REGEN-COV antibody combination to prevent Covid-19","volume":"385","author":"O'Brien","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2022.06.045_bib0024","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/jama.2021.24939","article-title":"Effect of subcutaneous casirivimab and imdevimab antibody combination vs placebo on development of symptomatic COVID-19 in early asymptomatic SARS-CoV-2 infection: a randomized clinical trial","volume":"327","author":"O'Brien","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.ijid.2022.06.045_bib0025","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2022.06.045_bib0026","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(22)00163-5","article-title":"Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"399","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ijid.2022.06.045_bib0027","unstructured":"Regeneron Pharmaceuticals, Inc., Regeneron's next generation monoclonal antibodies are active against all known variants of concern, including both omicron and delta. https:\/\/investor.regeneron.com\/static-files\/4aed42a1-3d26-48af-bd01-3f0c92938c11, 2021 (accessed 6 January 2022)."},{"key":"10.1016\/j.ijid.2022.06.045_bib0028","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.29058","article-title":"Risk factors associated with in-hospital mortality in a US national sample of patients with COVID-19","volume":"3","author":"Rosenthal","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ijid.2022.06.045_bib0029","doi-asserted-by":"crossref","first-page":"674","DOI":"10.15585\/mmwr.mm7018e1","article-title":"Effectiveness of Pfizer-BioNTech and Moderna vaccines against COVID-19 among hospitalized adults aged \u226565 Years \u2013 United States, January-March 2021","volume":"70","author":"Tenforde","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.ijid.2022.06.045_bib0030","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ijid.2022.06.045_bib0031","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.4920","article-title":"Prevalence of immunosuppressive drug use among commercially insured US adults, 2018\u20132019","volume":"4","author":"Wallace","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ijid.2022.06.045_bib0032","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jama.2020.1585","article-title":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China","volume":"323","author":"Wang","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ijid.2022.06.045_bib0033","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1056\/NEJMoa2108163","article-title":"REGEN-COV antibody combination and outcomes in outpatients with Covid-19","volume":"385","author":"Weinreich","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2022.06.045_bib0034","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","article-title":"Factors associated with COVID-19-related death using OpenSAFELY","volume":"584","author":"Williamson","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ijid.2022.06.045_bib0035","unstructured":"World Health Organization, WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020. https:\/\/www.who.int\/director-general\/speeches\/detail\/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-11-march-2020 2020, (accessed 16 September 2021)."},{"key":"10.1016\/j.ijid.2022.06.045_bib0036","doi-asserted-by":"crossref","first-page":"E7","DOI":"10.1038\/s41586-020-2202-3","article-title":"Author Correction: a new coronavirus associated with human respiratory disease in China","volume":"580","author":"Wu","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ijid.2022.06.045_bib0037","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N Engl J Med"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971222003800?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971222003800?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T10:34:38Z","timestamp":1715423678000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971222003800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":35,"alternative-id":["S1201971222003800"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2022.06.045","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.11.10.21265889","asserted-by":"object"}]},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2022.06.045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}